Mark Cobbold, M.D., Ph.D.Vice President, Discovery Oncology at AstraZeneca
Mark Cobbold, MD, PhD is an expert in translational immunology, with a particular focus on tumor immunology, immunotherapy and diagnostics. He is an Associate Geneticist, at the Massachusetts General Hospital Cancer Center and Member of the Faculty of Medicine at Harvard Medical School. Through basic research and coordinated set of clinical trials, Dr. Cobbold has made key discoveries that enhanced our understanding of the mechanisms of deregulation of signaling pathways, malignant transformation and T cell adoptive transfer immunotherapies.
Dr. Cobbold received his MD in 1995 from the University of Edinburgh, Scotland and began his scientific career in Birmingham in 2000 where, under Paul Moss, he studied cellular immunotherapy for patients who received stem cell transplants. He received his PhD from University of Birmingham in 2005. During this period he pioneered a novel T cell selection technology for manipulating and selecting antigen-specific cells for therapeutic use, and conducted a successful Phase I clinical trial using cytomegalovirus specific T-cells.
Currently, Dr. Cobbold’s laboratory focuses on understanding and investigation how the healthy human immune response can recognize and target cancerous cells, and when it fails, how it could be strengthened to identify this endogenous threat.